FOLH1 and cancer: Addressing critics’ concerns may involve a multifaceted approach that integrates advancements in molecular targeting with a deeper understanding of cancer biology, personalized medicine strategies, and the development of combination therapies to maximize the impact of PSMA-targeted treatments in clinical practice [44,77].